Q-omics provides the consensus-scored ATP5PBP5 profile across patient tissues and cancer cell-line models. ATP5PBP5 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ATP5PBP5 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ATP5PBP5 RNA expression shows 19,487 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where ATP5PBP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP5PBP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP5PBP5 survival associations across molecular data types. ATP5PBP5 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP5PBP5 RNA expression–survival associations across cancer types. High ATP5PBP5 expression shows unfavorable associations in LGG and LUSC, but favorable associations in KIRC, UCEC, COAD and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ATP5PBP5 RNA expression.
This table summarizes ATP5PBP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ATP5PBP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP5PBP5 shows lower tumor expression in KIRC, KICH, KIRP, LUSC, THCA and LUAD. The KIRC box plot shows higher ATP5PBP5 RNA expression in normal versus tumor tissue (log2 FC = −1.049, t-test p < 0.001).
This table shows molecular features associated with ATP5PBP5 in patient tissues and cancer cell lines. In patient samples, ATP5PBP5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
